恶性肿瘤放化疗致乙型肝炎病毒再激活防治进展

doi:10.3760/cma.j.issn.1673-422X.2014.03.007

摘要/Abstract

摘要： 乙型肝炎病毒感染者接受放化疗时可能出现病毒再激活，引起急性肝功能损伤。预防性抗病毒治疗可以减少病毒再激活及其相关病的发生，但尚缺乏统一的应用规范，因此需要多学科合作并开展更多前瞻性研究，以明确抗病毒治疗的个体化方案。

Abstract: Reactivation of hepatitis B virus (HBV) in cancer patients with HBV infection during or after chemoradiotherapy can lead to acute liver injury, even death. Antiviral prophylaxis can reduce the occurrence of HBV reactivation and its associated morbidity. However, there is no unified standard to guide antiviral treatment. Therefore, multidisciplinary collaboration and more prospective study should be carried out to identify the individual antiviral treatment plan.

Key words: Hepatitis B virus, Virus activation, Neoplasms, Drug therapy, Radiotherapy

汪孟森, 于甬华. 恶性肿瘤放化疗致乙型肝炎病毒再激活防治进展[J]. 国际肿瘤学杂志, 2014, 41(3): 184-187.

WANG Meng-Sen, YU Yong-Hua. Progress of prevention and cure of chemoradiotherapy-related hepatitis B virus reactivation[J]. Journal of International Oncology, 2014, 41(3): 184-187.

参考文献

［1］ Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in Chinadeclining HBV prevalence due to hepatitis B vaccination［J］. Vaccine, 2009, 27(47):65506557. ［2］ Chen WQ. Estimation of cancer incidence and mortality in China 20042005［J］. Chin J Oncol, 2009, 31(9):664668. ［3］ Wands J, Chura CM, Roll FJ, et al. Serial studies of hepatitis associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders［J］. Gastroenterology, 1975, 68(1):105112. ［4］ Yeo W, Chan PK, Zhong S, et al. Frequency of Hepatitis B Virus reactivation in cancer patients undergoing cykotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors［J］. J Med Viorl, 2000, 62(3):299307. ［5］ Kawsar HI, Shahnewaz J, Gopalakrishna KV, et al. Hepatitis B reactivation in cancer patients: role of prechemotherapy screening and antiviral prophylaxis［J］. Clin Adv Hematol Oncol, 2012, 10(6):370378. ［6］ Post A, Nagendra S. Reactivation of hepatitis B: pathogenesis and clinical implications［J］. Curr Infect Dis Rep, 2009, 11(2):113119. ［7］ Jang JW, Kwon JH, You CR, et al. Risk of HBV reactmation according to viral status and treatment intensity in patients with hepatocellular carcinoma［J］. Antivir Ther, 2011, 16(7):969977. ［8］ Ling WH, Soe PP, Pang AS, et al. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours［J］. Br J Cancer, 2013, 108(10):19311935. ［9］ Niitsu N, Hagiwara Y, Tanae K, et al. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large Bcell lymphoma after rituximab combination chemotherapy［J］. J Clin Oncol, 2010, 28(34):50975100. ［10］ Yeo W, Chan TC, Leung NW, et al.Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab［J］.J Clin Oncol, 2009, 27, 605611. ［11］ Sema Sezgin G, Bilal S, Coskun HS. Hepatitis B reactivation related to everolimus ［J］. World J Hepatol, 2013, 5(1):4345. ［12］ Fujimoto Y, Hashimoto N, Kinoshita M, et al. Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis［J］. Int J Clin Oncol, 2012, 17(3):290293. ［13］ Ohno M, Narita Y, Miyakita Y, et al.Reactivation of hepatitis B virus after glioblastoma treatment with temozolomide—case report［J］. Neurol Med Chir (Tokyo), 2011, 51(10):728731. ［14］ Kim IK, Kim BG, Kim W, et al. Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virusinfected patients undergoing cytotoxic chemotherapy for malignancy［J］. Antimicrob Agents Chemother， 2012, 56(11):55115519. ［15］ Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version)［J］. Zhonghua Liu Xing Bing Xue Za Zhi， 2011, 32(4):405415. ［16］ European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection［J］. J Hepatol, 2012, 57(1):167185. ［17］ Wong V, Chan H. Chronic hepatitis B: a treatment update［J］. Semin Liver Dis, 2013, 33(2):122129. ［18］ Yun J, Kim KH, Kang ES, et al. Prophylactic use of lamivudine for hepatitis B exacerbation in postoperative breast cancer patients receiving anthracycline based adjuvant chemotherapy［J］. Br J Cancer, 2011, 104(4):559563. ［19］ Chen XQ, Peng JW, Lin GN,et al. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAgpositive patients with diffuse large Bcell lymphoma undergoing prolonged rituximab therapy［J］. Med Oncol, 2012, 29(2):12371241. ［20］ Kim JH, Park JW, Kim TH, et al. Hepatitis B virus reactivation after threedimensional conformal radiotherapy in patients with hepatitis B virusrelated hepatocellular［J］. Int J Radiat Oncol Biol Phys, 2007, 69(3):813819. ［21］ Marcellin P, Chang TT, Lim SG, et al. Longterm efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigenpostitive chronic hepatitis B［J］. Hepatology, 2008, 48(3):750758. ［22］ Chen FW, Coyle L, Jones BE, et al. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease［J］. Liver Int, 2013, 33(8):12031210. ［23］ Kim SJ, Hsu C, Song YQ, et al. Hepatitis B virus reactivation in Bcell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group［J］. Eur J Cancer, 2013, 49(16):34863496. ［24］ Garg H, Sarin SK, Kumar M, et al. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acuteonchronic liver failure［J］. Hepatology, 2011, 53(3):774780. ［25］ Artz AS, Somerfield MR, Feld JJ, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases［J］. J Clin Oncol, 2010, 28(19):31993202.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.